Kelly Wilson Senior Associate

Senior Associate
DD +44 (0)20 7849 2867 T +44 (0)20 7831 9222 Email Kelly Download vCard

Kelly advises on a broad range of debt finance transactions, with a focus on fund finance and structured finance transactions.

Kelly acts for a varied client base including banks, credit fund lenders, speciality finance providers, alternative lenders, borrowers and sponsors and her experience includes advising on leverage facilities, subscription line facilities, receivables financing and asset backed lending, structured financings and specialty finance. She is dual qualified in England and Wales and South Africa, advising on domestic, European and and global cross-border transactions.

Expertise

Recent work

Specialty finance facility

Represented an alternative asset manager on a specialty finance facility made available for the purpose of funding and refinancing SME Loans in Sweden, Denmark and Finland.

Siris Capital

Acting for Siris Capital on the financing for their acquisition of Travelport Group and on the public-to-private acquisition of Equiniti Group.

Restructuring of a secured note programme

Advising a group of noteholders in connection with the restructuring of an existing secured note programme backed by certain receivables following the insolvency of one of the counterparties.

European financial services group

Representing a leading European financial services group in relation to a fund leverage facility made available to a French fund.

Subscription line facilities

Advising a leading private debt asset management firm on subscription line facilities for its unlevered and levered funds.

Venn Partners LLP

Advising ARA Venn on its appointment as delivery partner and subsequent establishment of a £3bn bond programme for the Affordable Homes Guarantee Scheme.

Asset reinsurance

Acting for an insurer in relation to a cross border asset reinsurance deal.

Jazz Pharmaceuticals plc

Advising Jazz Pharmaceuticals plc, a biopharmaceutical company based in Ireland, on financing aspects of its acquisition of GW Pharmaceuticals plc for a total consideration of $7.2bn, announced in February 2021.

See all